<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04331730</url>
  </required_header>
  <id_info>
    <org_study_id>AKST4290-205</org_study_id>
    <nct_id>NCT04331730</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD</brief_title>
  <acronym>PHTHALO-205</acronym>
  <official_title>A Double-Masked, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy of Oral AKST4290 With Loading Doses of Aflibercept in Patients With Newly Diagnosed Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkahest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkahest, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of AKST4290 in combination with aflibercept&#xD;
      injections in subjects with newly diagnosed neovascular age-related macular degeneration&#xD;
      (nAMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-masked, placebo-controlled, dose-ranging, multicenter study to&#xD;
      assess the efficacy and safety of AKST4290 administered orally at 400 mg twice per day or 800&#xD;
      mg b.i.d. in combination with intravitreal aflibercept injections (IAI), in subjects with&#xD;
      newly diagnosed neovascular age-related macular degeneration (nAMD) who are naïve to&#xD;
      treatment with anti-vascular endothelial growth factor (anti-VEGF) medications in the study&#xD;
      eye. Subjects will be treated with AKST4290 800 mg daily, 1600 mg daily, or placebo for a&#xD;
      total of 36 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Actual">September 16, 2021</completion_date>
  <primary_completion_date type="Actual">August 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in Best Corrected Visual Acuity (BVCA)</measure>
    <time_frame>Screening to Week 40</time_frame>
    <description>Mean change from baseline in BCVA per the Early Treatment Diabetic Retinopathy Study (ETDRS) testing method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first use of rescue therapy</measure>
    <time_frame>Baseline to Week 40</time_frame>
    <description>Time to first use of intravitreal aflibercept injection, as needed (AKST4290 Arms only). UNITS: days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of aflibercept injections received</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Mean number of intravitreal aflibercept injections received. UNITS: number of injections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with Best Corrected Visual Acuity (BCVA) change of ≥ 15 letters</measure>
    <time_frame>Screening to Week 40</time_frame>
    <description>Proportion of subjects with BCVA change of ≥ 15 letters at Week 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Central Subfield Thickness (CST)</measure>
    <time_frame>Screening to Week 40</time_frame>
    <description>Mean change in CST compared with control. UNITS: microns</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and intensity of adverse events</measure>
    <time_frame>Screening to Week 40</time_frame>
    <description>Safety as assessed by incidence and intensity of adverse events.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean change in Best Corrected Visual Acuity (BCVA) per the Early Treatment Diabetic Retinopathy Study (ETDRS) testing method</measure>
    <time_frame>Screening to Week 40</time_frame>
    <description>Mean change in BCVA per the ETDRS testing method in AKST4290 arms as compared with control.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Low-Luminance Visual Acuity (LLVA)</measure>
    <time_frame>Baseline to Week 36</time_frame>
    <description>Changes in LLVA.</description>
  </other_outcome>
  <other_outcome>
    <measure>Dose response as assessed by mean change in Best Corrected Visual Acuity (BCVA) and mean number of injections in</measure>
    <time_frame>Screening to Week 40</time_frame>
    <description>Dose response as assessed by mean change in BCVA and mean number of injections in all treatment arms by study visit.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in National Eye Institute Visual Function Questionnaire-39 (NEI-VFQ-39)</measure>
    <time_frame>Screening to Week 40</time_frame>
    <description>Scale is 0-100. Higher number corresponds to better visual function.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>AKST4290 (800 mg) + Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 400 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AKST4290 (1600 mg) + Aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 800 mg AKST4290 twice daily for 36 weeks, in combination with intravitreal aflibercept injection treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Aflibercept</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo for 36 weeks, in combination with intravitreal aflibercept injection treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKST4290</intervention_name>
    <description>Oral AKST4290</description>
    <arm_group_label>AKST4290 (1600 mg) + Aflibercept</arm_group_label>
    <arm_group_label>AKST4290 (800 mg) + Aflibercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo</description>
    <arm_group_label>Placebo + Aflibercept</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Aflibercept intravitreal injection</description>
    <arm_group_label>AKST4290 (1600 mg) + Aflibercept</arm_group_label>
    <arm_group_label>AKST4290 (800 mg) + Aflibercept</arm_group_label>
    <arm_group_label>Placebo + Aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Men and women with newly diagnosed active CNV secondary to AMD, diagnosed by a retinal&#xD;
             specialist with all the following characteristics and ophthalmic inclusion criteria&#xD;
             applied to the study eye, as assessed by a central reader:&#xD;
&#xD;
               -  Has been examined by a retinal specialist and found to be eligible to receive&#xD;
                  Intravitreal Aflibercept Injection (IAI) in the study eye.&#xD;
&#xD;
               -  No prior treatment for nAMD in the study eye.&#xD;
&#xD;
               -  Study eye has not undergone pars plana vitrectomy or glaucoma filtering surgery.&#xD;
&#xD;
               -  Participation in studies of investigational drugs must have been discontinued&#xD;
                  within 30 days or 5 half-lives of the drug (whichever was longer) prior to&#xD;
                  screening.&#xD;
&#xD;
               -  CST thickness ≥ 250 microns on SD-OCT (exclusive of subretinal pigment epithelial&#xD;
                  fluid, inclusive of SRF).&#xD;
&#xD;
               -  Presence of SRF and/or IRF on SD-OCT.&#xD;
&#xD;
               -  Total lesion size not greater than 12 disc areas (30.48 mm2) (1 disc area = 2.54&#xD;
                  mm2) on FA.&#xD;
&#xD;
               -  If present, subretinal hemorrhage must comprise &lt; 50% of the total lesion area on&#xD;
                  FA, SD-OCT, or FP/FAF.&#xD;
&#xD;
               -  No subfoveal fibrosis or atrophy on FA, SD-OCT, or FP/FAF.&#xD;
&#xD;
               -  Active CNV membranes with subfoveal leakage or juxtafoveal leakage too close for&#xD;
                  laser photocoagulation.&#xD;
&#xD;
          -  BCVA in the study eye between 70 and 24 letters inclusive.&#xD;
&#xD;
          -  Body mass index (BMI) between (and inclusive of) 18 and 40 at screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Participation in studies of investigational drugs within 30 days or 5 half-lives of&#xD;
             the drug (whichever was longer) prior to screening.&#xD;
&#xD;
          -  Known hypersensitivity to the active substance or any of the excipients of AKST4290 or&#xD;
             aflibercept.&#xD;
&#xD;
          -  Active or suspected ocular or periocular infection and/or active, severe intraocular&#xD;
             inflammation.&#xD;
&#xD;
          -  Any form of macular degeneration that is not age-related (e.g., Best's disease,&#xD;
             Stargardt's disease, Sorsby's disease).&#xD;
&#xD;
          -  Additional disease in the study eye that could compromise BCVA (i.e., uncontrolled&#xD;
             glaucoma (IOP &gt;24) with visual field loss, clinically significant diabetic macular&#xD;
             edema, history of ischemic optic neuropathy or retinal vascular occlusion,&#xD;
             vitreomacular traction, high myopia &gt; 6 diopters, or genetic disorders such as&#xD;
             retinitis pigmentosa).&#xD;
&#xD;
          -  Presence of RPE tears or rips in the study eye.&#xD;
&#xD;
          -  Anterior segment and vitreous abnormalities in the study eye that would preclude&#xD;
             adequate visualization with FP/FAF, FA, or SD-OCT.&#xD;
&#xD;
          -  Intraocular surgery in the study eye within 3 months prior to screening.&#xD;
&#xD;
          -  Aphakia or total absence of the posterior capsule (yttrium aluminum garnet [YAG] laser&#xD;
             capsulotomy permitted in an eye with a posterior chamber intraocular lens if performed&#xD;
             a minimum of 1 month prior to enrollment) in the study eye.&#xD;
&#xD;
          -  Known allergy to fluorescein sodium.&#xD;
&#xD;
          -  Significant alcohol or drug abuse within past 2 years.&#xD;
&#xD;
          -  Based on ECG reading, subjects with a risk of QT prolongation.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alkahest Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Alkahest, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of FL</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internationale Innovative Ophthalmochirurgie GbR</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>nordBLICK Augenklinik Bellevue</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augentagesklinik Rheine</name>
      <address>
        <city>Rheine</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Dél-pesti Kórház (Jahn Ferenc South-Pest Hospital)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvédség Egészségügyi Központ, Szemészeti Osztály (Medical Centre, Hungarian Defence Forces, Ophthalmology Department)</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház (Borsod-Abaúj-Zemplén County Hospital and University Teaching Hospital)</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GANGLION Orvosi Központ</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Általános Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Szemészeti Klinika, (University of Szeged Faculty of Medicine, Albert-Szent Gyorgyi Health Care, Department of Ophthalmology)</name>
      <address>
        <city>Szekszárd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tęczówka (IRIS)</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Ośrodek Okulistyczny Oculomedica (Specialized Eye Center Oculomedica)</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PROVISUS Sp. z o.o.</name>
      <address>
        <city>Częstochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimum Profesorskie Centrum Okulistyki</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Dietla 19 Sp zoo</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chirurgii Siatkówki i Ciała Szklistego Medical University in Lublin</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital św. Wojciecha</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ArtOptica Salon Okulistyczno</name>
      <address>
        <city>Suwałki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne UNO-MED</name>
      <address>
        <city>Tarnów</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Clinical Hospital of the MSWiA</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Degeneration</keyword>
  <keyword>Retinal Degeneration</keyword>
  <keyword>Retinal Diseases</keyword>
  <keyword>Eye Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

